Stay updated on Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial
Sign up to get notified when there's something new on the Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial page.

Latest updates to the Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedA new Revision: v3.4.2 tag was added. A non-critical funding/operating status notice was removed; core trial content and page functionality remain unchanged.SummaryDifference0.2%

- Check21 days agoChange DetectedA site-wide notice about a lapse in government funding and NIH operating status was added, and the site revision was updated from 3.4.0 to 3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check28 days agoChange DetectedUI and metadata updates include showing a glossary option and adding metadata fields such as Results First Posted, Certification/Extension First Posted, Last Update Submitted that Met QC Criteria, and Last Update Posted, with the revision noted as v3.4.0; older related fields were removed.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; no user-facing study details appear to be affected.SummaryDifference0.0%

- Check63 days agoChange DetectedLocations section updated with numerous new sites across the United States (California, Massachusetts, New Jersey, New York, Ohio, Tennessee, Texas) and China (Anhui, Beijing Municipality, Chongqing Municipality, Fujian, Guangdong, etc.), plus the revision tag v3.3.3. Old location entries appear to have been replaced to reflect the current site list.SummaryDifference2%

- Check92 days agoChange DetectedMinor wording changes in the Publications section and a page revision label (Revision: v3.3.2) were added; these do not affect core study information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial page.